文献速递膀胱癌与上尿路尿路上皮癌

PTEN缺失在上尿路尿路上皮癌根治性肾输尿管切除术患者中的频率与预后价值

Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.
PubMed 文献 · J Urol · 2017-07-12

回顾性分析7家机构1991至2008年间611例接受根治性肾输尿管切除术的上尿路尿路上皮癌患者,PTEN免疫组化染色缺失45例(7.4%)。PTEN缺失与更晚的病理分期、更高的分级、淋巴结转移及淋巴血管侵犯相关,多变量Cox回归中仅与总死亡率相关(HR 1.69,95%CI 1.09-2.61,p=0.02)。

要点

  • PTEN蛋白缺失在上尿路尿路上皮癌中少见,611例中45例(7.4%)染色缺失。
  • PTEN缺失与更晚病理分期、更高分级、淋巴结转移及淋巴血管侵犯显著相关。
  • 多变量调整后PTEN缺失仅与总死亡率相关(HR 1.69,95%CI 1.09-2.61,p=0.02)。

核心结论

  • 在接受根治性肾输尿管切除术的上尿路尿路上皮癌患者中,PTEN蛋白表达缺失少见,但与更高分级、更晚分期及淋巴结转移等生物学侵袭性特征相关。
  • PTEN表达缺失与总死亡率相关,PTEN缺失似乎在这一相对较小的患者群体中促进更差结局。

研究设计与样本

  • 回顾性分析1991年至2008年间在总共7家机构接受根治性肾输尿管切除术的611例上尿路尿路上皮癌患者记录,中位随访23个月。
  • 采用组织微阵列和免疫组化PTEN染色(单克隆抗体),建立单变量和多变量Cox回归模型分析PTEN蛋白表达与疾病复发、癌症特异性死亡及总死亡率的关系。

主要发现

  • 45例(7.4%)PTEN染色缺失。
  • PTEN缺失患者与PTEN表达患者相比,病理肿瘤分期和分级显著更晚(p<0.001),淋巴结转移率更高(p<0.01),淋巴血管侵犯率更高(p<0.001)。
  • 单变量Cox回归分析中,PTEN缺失与疾病复发、癌症特异性死亡及总死亡率相关。
  • 多变量Cox回归分析调整标准临床病理特征后,PTEN缺失仅与总死亡率相关(HR 1.69,95%CI 1.09-2.61,p=0.02)。

关键数值与推荐

  • PTEN免疫组化染色缺失定义为染色缺失,611例中45例(7.4%)缺失。
  • 多变量分析中PTEN缺失与总死亡率相关:HR 1.69,95%CI 1.09-2.61,p=0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To our knowledge the frequency and prognostic significance of PTEN protein expression in upper tract urothelial carcinoma have not yet been investigated in large studies. We analyzed PTEN protein status and its association with disease recurrence and survival outcomes in a large, multi-institutional upper tract urothelial carcinoma cohort. MATERIALS AND METHODS: We retrospectively analyzed the records of 611 patients with upper tract urothelial carcinoma treated with radical nephroureterectomy between 1991 and 2008 at a total of 7 institutions. Median followup was 23 months. Tissue microarrays and immunohistochemical PTEN staining (monoclonal antibody) were performed. Univariable and multivariable Cox regression models were created to address the association of PTEN protein expression with disease recurrence, and cancer specific and overall mortality. RESULTS: PTEN staining was absent in 45 cases (7.4%). Patients with PTEN loss had significantly advanced pathological tumor stage and grade (p <0.001), and higher rates of lymph node metastasis (p <0.01) and lymphovascular invasion (p <0.001) compared to patients with PTEN expression. PTEN loss was associated with disease recurrence, and cancer specific and overall mortality on univariable Cox regression analyses. However, on multivariable Cox regression analyses adjusted for the effect of standard clinicopathological features PTEN loss was only associated with overall mortality (HR 1.69, 95% CI 1.09-2.61, p = 0.02). CONCLUSIONS: In patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma loss of PTEN protein expression is rare but associated with features of biologically aggressive disease such as higher grade and stage as well as lymph node metastasis. Loss of PTEN expression was associated with overall mortality. PTEN loss seemed to promote worse outcomes in this relatively small group of patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Rieken M, Shariat SF, Karam JA, et al. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017. PMID: 28709887. doi:10.1016/j.juro.2017.06.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。